Suppr超能文献

针对肺炎克雷伯菌的鼠单克隆抗体可预防致死性内毒素血症及由荚膜型肺炎克雷伯菌引起的实验性感染。

Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae.

作者信息

Mandine E, Salles M F, Zalisz R, Guenounou M, Smets P

机构信息

Centre de Recherches Immunologiques Roussel-Uclaf, Laboratoires Cassenne, Osny, France.

出版信息

Infect Immun. 1990 Sep;58(9):2828-33. doi: 10.1128/iai.58.9.2828-2833.1990.

Abstract

To prepare monoclonal antibodies (MAbs) directed against the core-lipid A fractions of smooth lipopoly-saccharide (LPS) from Klebsiella pneumoniae O1:K2, we immunized BALB/c mice with the LPS-associated proteins plus LPS. This preparation exposed the core-lipid A moiety, which is normally hidden in the micellar structure of classical LPS preparations. Among 10 MAbs selected for their reactivity with LPS-associated proteins plus LPS from K. pneumoniae O1:K2, 6 (3A3, 3C2, 3C4, 7D2, 11C3, and 12B6) were directed against the core fraction and 2 (6C5 and 10A5) were directed against the lipid A fraction. Only one (2A4) recognized the O antigen, and one (6D5) had an undefined specificity. When injected before challenge with K. pneumoniae O1:K2 LPS in galactosamine-sensitized mice, five of the MAbs (3C4, 6D5, 7D2, 11C3, and 12B6) provided protection in this model of lethal endotoxemia. MAb 7D2 was also protective in an experimental infection with capsulated K. pneumoniae O1:K2.

摘要

为制备针对肺炎克雷伯菌O1:K2光滑型脂多糖(LPS)核心脂质A部分的单克隆抗体(MAb),我们用LPS相关蛋白加LPS免疫BALB/c小鼠。这种制剂暴露了核心脂质A部分,该部分通常隐藏在经典LPS制剂的胶束结构中。在因与肺炎克雷伯菌O1:K2的LPS相关蛋白加LPS反应性而挑选出的10种MAb中,6种(3A3、3C2、3C4、7D2、11C3和12B6)针对核心部分,2种(6C5和10A5)针对脂质A部分。只有一种(2A4)识别O抗原,一种(6D5)具有不确定的特异性。在用半乳糖胺致敏的小鼠中,在用肺炎克雷伯菌O1:K2 LPS攻击前注射时,其中5种MAb(3C4、6D5、7D2、11C3和12B6)在这种致死性内毒素血症模型中提供了保护。MAb 7D2在肺炎克雷伯菌O1:K2的实验性感染中也具有保护作用。

相似文献

2
Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection.
Infect Immun. 1997 May;65(5):1754-60. doi: 10.1128/iai.65.5.1754-1760.1997.
3
Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections.
Vaccine. 2008 Oct 16;26(44):5649-53. doi: 10.1016/j.vaccine.2008.07.100. Epub 2008 Aug 24.
7
Phenotypic whole-cell screening identifies a protective carbohydrate epitope on .
MAbs. 2022 Jan-Dec;14(1):2006123. doi: 10.1080/19420862.2021.2006123.
10
Cross-specificity of protective human antibodies against Klebsiella pneumoniae LPS O-antigen.
Nat Immunol. 2018 Jun;19(6):617-624. doi: 10.1038/s41590-018-0106-2. Epub 2018 May 14.

引用本文的文献

1
Lipopolysaccharide as a Vaccine Target and the Role of Antibodies in Protection from Disease.
Vaccines (Basel). 2024 Oct 17;12(10):1177. doi: 10.3390/vaccines12101177.
2
Current Stage in the Development of Klebsiella pneumoniae Vaccines.
Infect Dis Ther. 2021 Dec;10(4):2157-2175. doi: 10.1007/s40121-021-00533-4. Epub 2021 Sep 2.
3
Progress towards the development of Klebsiella vaccines.
Expert Rev Vaccines. 2019 Jul;18(7):681-691. doi: 10.1080/14760584.2019.1635460. Epub 2019 Jun 28.
4
Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.
Hum Vaccin Immunother. 2013 Mar;9(3):497-505. doi: 10.4161/hv.23225. Epub 2012 Dec 18.
8
Salicylate-enhanced exposure of Klebsiella pneumoniae subcapsular components.
Infection. 1995 Nov-Dec;23(6):371-7. doi: 10.1007/BF01713568.

本文引用的文献

2
Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.
Am J Med. 1980 Mar;68(3):332-43. doi: 10.1016/0002-9343(80)90101-1.
4
Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.
N Engl J Med. 1982 Nov 11;307(20):1225-30. doi: 10.1056/NEJM198211113072001.
5
Aspects of beneficial endotoxin-mediated effects.
Klin Wochenschr. 1982 Jul 15;60(14):746-8. doi: 10.1007/BF01716569.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验